A paper published in the journal Science on August 8 suggests that it may be possible to speed up the drug discovery process.

Vir Biotechnology Inc. plans to start a mid-to-late stage trial of the company’s Covid-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus.

Convalescent therapy has been touted as a fast, effective response to Covid-19, but a new therapy by GigaGen Inc. could be even more promising.

Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.

Researchers are developing simpler Covid-19 diagnostic tests for use outside of labs in an effort to make mass testing available, fast and inexpensive.

Johnson & Johnson’s Janssen Pharmaceutical Companies entered into an agreement with the U.S. government for the large-scale domestic manufacturing and delivery in the United States of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use following approval or Emergency Use Authorization by the Food and Drug Administration.

According to a study published in the journal Science Advances, an international team of researchers led by neuroscientists at Harvard Medical School uncovered which olfactory cell types are most vulnerable to infection by SARS-CoV-2, which causes Covid-19.

Merck is joining the ranks of pharmaceutical companies that have a Covid-19 vaccine candidate in clinical development and will move the drug manufacturer’s candidate into clinical trials in third-quarter 2020.

This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.

The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.